[1] Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014, 59: 1174-1197.
[2] Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med, 2015, 373: 438-447.
[3] Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010, 362: 1082-1089.
[4] Norata GD, Tsimikas S, Pirillo A, et al. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci, 2015, 36: 675-687.
[5] Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol, 2011, 31: 513-519.
[6] Tai ES, Corella D, Demissie S, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr, 2005, 135: 397-403.
[7] Blais P, Lin M, Kramer JR, et al. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci, 2016, 61: 1714-1720.
[8] Karim MF, Al-Mahtab M, Rahman S, et al. Non-alcoholic fatty liver disease (NAFLD)--a review. Mymensingh Med J, 2015, 24: 873-880.
[9] Souza MR, Diniz Mde F, Medeiros-Filho JE, et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol, 2012, 49: 89-96.
[10] Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism, 2016, 65: 1109-1123.
[11] Li H, Han Y, Qi R, et al. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovasc Res, 2015, 107: 579-589.
[12] Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res, 2013, 112: 1479-1490.
[13] Wree A, Schlattjan M, Bechmann LP, et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism, 2014, 63: 1542-1552.
[14] Lee HY, Birkenfeld AL, Jornayvaz FR, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology, 2011, 54: 1650-1660.
[15] Duivenvoorden I, Teusink B, Rensen PC, et al. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes, 2005, 54: 664-671.
[16] Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42: 987-1000.
[17] Uppal V, Mansoor S, Furuya KN. Pediatric non-alcoholic fatty liver disease. Curr Gastroenterol Rep, 2016, 18: 24.
[18] Tilg H, Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care, 2010, 13: 391-396.
[19] Li MR, Zhang SH, Chao K, et al. Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World J Gastroenterol, 2014, 20: 14010-14017.
[20] Walker RW, Sinatra F, Hartiala J, et al. Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children. Obesity (Silver Spring), 2013, 21: E790-E797.
[21] Puppala J, Bhrugumalla S, Kumar A, et al. Apolipoprotein C3 gene polymorphisms in Southern Indian patients with nonalcoholic fatty liver disease. Indian J Gastroenterol, 2014, 33: 524-529.
[22] Kozlitina J, Boerwinkle E, Cohen JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011, 53: 467-474.
[23] Sentinelli F, Romeo S, Maglio C, et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis, 2011, 10:93.
[24] Romero-Gomez M. APOC3 polymorphisms and non-alcoholic fatty liver disease: resolving some doubts and raising others. J Hepatol, 2011, 55: 1184-1186. |
